Story

Biohaven Stock Jumps 7% on $795 Million Epilepsy Drug Deal with SK Biopharmaceuticals

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20262 min read
Biohaven Stock Jumps 7% on $795 Million Epilepsy Drug Deal with SK Biopharmaceuticals
Text size
Background

Biohaven Ltd. (NYSE:BHVN) shares rose 7% on Wednesday following the announcement of a strategic global licensing agreement with SK Biopharmaceuticals for its Kv7 ion channel platform. The deal, centered on the epilepsy treatment candidate opakalim, provides Biohaven with significant upfront capital and potential future payments.

Deal Highlights

Under the terms of the agreement, SK Biopharmaceuticals will make substantial payments to Biohaven, which will de-risk the development program for the smaller biotech firm. The key financial components of the deal include:

  • Total Potential Value: Up to $795 million in upfront and milestone payments related to the Kv7 platform.
  • Upfront Cash: Biohaven will receive $400 million in cash, consisting of $350 million at closing and an additional $50 million in 2027.
  • Future Milestones: The company is eligible for an additional $150 million tied to development and regulatory milestones.
  • Royalties: Biohaven will earn tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim, plus royalties on global net sales.

SK Biopharmaceuticals will assume responsibility for all future Kv7 program costs, including certain specified obligations totaling $245 million, according to the announcement.

Strategic Rationale

Sample IUX Markets – In-articleAd

The partnership leverages the strengths of both companies. SK Biopharmaceuticals gains a late-stage asset that complements its existing commercial footprint in the epilepsy market, where it already sells XCOPRI for partial-onset seizures through a commercial team of over 150 professionals in the U.S.

For Biohaven, the agreement provides a significant infusion of non-dilutive capital while transferring the financial risk of future clinical development and commercialization to its partner. The lead candidate from the platform, opakalim, is a selective Kv7.2/7.3 potassium channel activator currently in a Phase 2/3 trial for focal epilepsy.

Next Steps and Market Impact

Investors reacted positively to the deal's financial structure and strategic fit, driving Biohaven's stock higher. The next major catalyst for the program will be topline results from the RISE3 trial, which are expected in the second half of 2026.

The closing of the transaction is subject to customary conditions, including completion of review under the Hart-Scott-Rodino Antitrust Improvements Act in the U.S.

Read next

More on Stocks
Back to latest news

LATEST